Abstract
Epidemiological evidences suggest that chronic use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) might be associated with a reduced risk of gastrointestinal cancers, including gastric cancer. The pre-cancerous gastric lesions and gastric cancers over-expressed cyclooxygenase (COX)-2. This overexpression not only is associated with Helicobacter pylori infection, but also maybe due to exposure to carcinogens. Targeted inhibition of COX, especially the COX-2 isoform, can lead to growth inhibition and apoptosis of gastric cancer in vitro. Various mechanisms, including COX-dependent and COX-independent pathways, have been identified and will be discussed in this article. Animal xenograft models have confirmed the tumor suppressing effects of COX-2 inhibitors. Human studies are underway to examine the use of COX-2 inhibitor in the treatment of pre-cancerous lesions. COX-2 inhibitors have a promising role in the prevention and treatment of gastric cancer.
Keywords: gastric cancer, apoptosis, prostaglandin, cyclooxygenase, prevention, epidemiology, premalignant lesions, intervention
Current Pharmaceutical Design
Title: Cyclooxygenase-2 Inhibition and Gastric Cancer
Volume: 9 Issue: 27
Author(s): Xiao Hua Jiang and C. Y. Wong
Affiliation:
Keywords: gastric cancer, apoptosis, prostaglandin, cyclooxygenase, prevention, epidemiology, premalignant lesions, intervention
Abstract: Epidemiological evidences suggest that chronic use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) might be associated with a reduced risk of gastrointestinal cancers, including gastric cancer. The pre-cancerous gastric lesions and gastric cancers over-expressed cyclooxygenase (COX)-2. This overexpression not only is associated with Helicobacter pylori infection, but also maybe due to exposure to carcinogens. Targeted inhibition of COX, especially the COX-2 isoform, can lead to growth inhibition and apoptosis of gastric cancer in vitro. Various mechanisms, including COX-dependent and COX-independent pathways, have been identified and will be discussed in this article. Animal xenograft models have confirmed the tumor suppressing effects of COX-2 inhibitors. Human studies are underway to examine the use of COX-2 inhibitor in the treatment of pre-cancerous lesions. COX-2 inhibitors have a promising role in the prevention and treatment of gastric cancer.
Export Options
About this article
Cite this article as:
Jiang Hua Xiao and Wong Y. C., Cyclooxygenase-2 Inhibition and Gastric Cancer, Current Pharmaceutical Design 2003; 9 (27) . https://dx.doi.org/10.2174/1381612033453983
DOI https://dx.doi.org/10.2174/1381612033453983 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Oxygen in Cancer: Looking Beyond Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Insights in microRNAs Biology
Current Topics in Medicinal Chemistry Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Melanoma and Epigenetic Treatment: Past and Future
Anti-Cancer Agents in Medicinal Chemistry May Gender or Ethnicity Affect Delta Over Baseline Values Obtained by 13-C Urea Breath Test?
Reviews on Recent Clinical Trials Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Meet Our Regional Editor
Current Gene Therapy Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry RNA Interference-Based Gene Silencing in Mice: The Development of a Novel Therapeutical Strategy
Current Pharmaceutical Design New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design A Systematic in-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates
Current Genomics Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Update on Cancer Related Issues of Mesenchymal Stem Cell-Based Therapies
Current Stem Cell Research & Therapy 68Ga/64Cu PSMA Bio-Distribution in Prostate Cancer Patients: Potential Pitfalls for Different Tracers
Current Radiopharmaceuticals Computer-Aided Design of Antimicrobial Peptides
Current Pharmaceutical Analysis Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy